^
    Back
    Association details:
    Biomarker:HRD
    Cancer:Prostate Cancer
    Drug:Talzenna (talazoparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lancet Oncol
    Title:

    Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

    Published date:
    08/10/2021
    Excerpt:
    Talazoparib showed durable antitumour activity in men with advanced metastatic castration-resistant prostate cancers with DDR-HRR gene alterations who had been heavily pretreated. 
    DOI:
    10.1016/S1470-2045(21)00376-4
    Trial ID:
    Talapro-1